Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $27K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $113K.

Context

  • Cost of revenue amounted to 0.5% of revenue in FY2025.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $27K or moves back toward the trailing-twelve-month quarterly average of $28.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27K— QoQ
Last fiscal yearDec 2025
$325K— YoY
LTMMar 2026
$113K+31.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
325K USD
Year-over-year change
—

Cost of Revenue vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.4% is the 5th highest of 8, against a peer median of +31.7%.
BDTX Competitors
Cost of Revenue for BDTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$21.94M USD——77.7%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$10.68M USD+89.7%—18096.6%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$6.99M USD+800.8%+50.4%48.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$3.96M USD+31.7%+252.4%7.8%
IVAInventiva S.A.FY2025€2.8M EUR-28.0%+41.1%62.4%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$1.95M USD-96.9%+0.0%17.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.21M USD——1.7%
IMRXImmuneering CorporationLTM Mar 2026$793.21K USD+354.2%+64.1%—
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$113K USD+31.4%——
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$101K USD-104.8%-1.1%44.9%
Peer median (excluding BDTX) —+31.7%+45.8%46.5%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000070M
Cost of Revenue00437K0325K
Gross Profit00(437K)069.68M
Gross Margin————99.5%
Research & Development96.83M64.44M58.91M51.31M33.56M
Selling, General & Admin30.04M28.39M27.11M27.47M16.57M
Operating Expenses126.87M92.83M86.02M78.78M49.81M
Depreciation & Amortization205K508K437K343K325K
EBITDA(125.39M)(90.66M)(82.01M)(69.33M)22.69M
EBITDA Margin————32.4%
Operating Income(126.87M)(92.83M)(86.46M)(78.78M)19.87M
Operating Margin————28.4%
Interest Income3.46M2.03M1.92M2.18M4.06M
Interest Expense00000
Other Income / Expenses1.28M1.66M4.02M9.11M2.5M
Income Before Tax(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Pre-Tax Margin————32.0%
Income Tax Expense00000
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Net Margin————32.0%
EPS (Basic)(3.47)(2.52)(1.88)(1.27)0.39
EPS (Diluted)(3.47)(2.52)(1.88)(1.27)0.39
Weighted Avg Shares36.19M36.23M43.95M55.03M56.87M
Weighted Avg Shares (Diluted)36.19M36.23M43.95M55.03M57.56M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.